Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 years
Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Carol J. Swallow(Princess Margaret Cancer Centre), Rebecca A. Gladdy(Lunenfeld-Tanenbaum Research Institute), Rick L. Haas(Leiden University), Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Frits van Coevorden(The Netherlands Cancer Institute), Deanna Ng(Mount Sinai Hospital), Chandrajit P. Raut(Brigham and Women's Hospital), Sylvie Bonvalot(Institut Curie), D. Strauß(Royal Marsden Hospital), Charles Honoré(Institut Gustave Roussy), Alessandro Gronchi(University of Milan), Winan J. van Houdt(Diakonessenhuis hospital), Nikolaos Vassos(Royal Marsden NHS Foundation Trust), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Lorenzo Conti(Fondazione IRCCS Istituto Nazionale dei Tumori), Eberhard Stoeckle(Institut Bergonié), Yvonne Schrage(Leiden University Medical Center)
Cited by 56
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k